Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia

Autor: Haluk Demiroglu, Yahya Buyukasik, Hakan Goker, Salih Aksu, Rafiye Ciftciler
Rok vydání: 2019
Předmět:
Adult
Male
Cancer Research
medicine.medical_specialty
Adolescent
Neutrophils
medicine.medical_treatment
Blood count
Kaplan-Meier Estimate
Hematopoietic stem cell transplantation
Gastroenterology
Leukocyte Count
Young Adult
03 medical and health sciences
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Overall survival
Humans
Transplantation
Homologous
Medicine
In patient
Aged
Retrospective Studies
Platelet Count
business.industry
Remission Induction
Cytarabine
Hematopoietic Stem Cell Transplantation
Complete remission
Myeloid leukemia
Hematology
Middle Aged
Progression-Free Survival
Transplantation
Leukemia
Myeloid
Acute
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Female
Bone marrow
Idarubicin
business
Follow-Up Studies
030215 immunology
Zdroj: Clinical Lymphoma Myeloma and Leukemia. 19:e205-e212
ISSN: 2152-2650
Popis: Background Patients who achieve complete remission (CR) with incomplete blood count recovery (CRi) in acute myeloid leukemia (AML) have inferior overall survival and lower progression-free survival. The aim of this study was to define whether blood count recovery-based CR before allogeneic hematopoietic stem cell transplantation (alloHSCT) had an impact on survival in patients with AML. Materials and Methods This study has been performed in a retrospective manner. One hundred one patients with AML who received an alloHSCT in our transplant center at Hacettepe University Hospital between the years 2001 and 2018 were evaluated. CRi were defined as bone marrow CR with absolute neutrophil count Results A total of 101 patients were entered into the study between 2001 and 2018. Median follow-up for all survivors was 38 months (range, 6-220 months). The 5-year overall survival for patients who were in CRi and patients who were in CR before transplantation were 58% and 67%, respectively (P = .68). The 5-year progression-free survival for patients who were in CRi and patients who were in CR before transplantation were 68% and 64%, respectively (P = .99). Conclusion In conclusion, we observed equivalent posttransplant outcomes between patients who were in CR and patients who were in CRi before alloHSCT. We assume that alloHSCT eliminated the negative effect of pre-transplant blood count levels.
Databáze: OpenAIRE
Externí odkaz: